Biosimilar Medicines Reading List

Position Paper – Unitary SPC & Unified Mechanism for the Granting of SPCs

Positioning Statements on Physician-led Switching for Biosimilar Medicines

Positioning statements on physician-led switching for biosimilar medicines (October 2021)

Biosimilar medicines group position on physician-led switching (July 2015)

Biosimilar medicines group position on biologic pharmacy substitution (September 2020)

Position Paper. Incentives Review The Orphan and Paediatric Incentives

Electronic product information: from principles to actions. AESGP, EFPIA and Medicines for Europe reflections on EMAHMA – EC Key principles for electronic product information

Biosimilars in the EU – Information guide for healthcare professionals – unofficial Ukrainian translation now available

Open unofficial Ukrainian translation

Filling the gap: How off-patent medicines can improve the equity and quality of cancer care

Filling the gap: How off-patent medicines can improve the equity and quality of cancer care

The total clinical experience with biosimilar medicines exceeds 2 billion patient treatment days

Biosimilar medicines are available in therapy areas which represent 65% of the biologics market by value